Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Antengene's 2025 Results Show Major Growth and Strategic Partnerships as They Move Toward Profitability Antengene Corporation Limited reports its full-year results for 2025, highlighting significant achievements and partnerships as it aims for 2026 profitability.

Antengene's 2025 Results Show Major Growth and Strategic Partnerships as They Move Toward Profitability #China #Shanghai #biotechnology #Antengene #T-Cell_Engagers

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Antengene to Showcase Innovative Biotech Advancements at AACR 2026 Antengene Corporation Limited will reveal groundbreaking preclinical data on its dual-function T cell engagers at AACR 2026, focusing on ADCs.

Antengene to Showcase Innovative Biotech Advancements at AACR 2026 #United_States #San_Diego #Antengene #ADCs #TCEs

pharmaphorum

@pharmaphorum.bsky.social

4 weeks ago

Alnylam bets on Tenaya RNAi tech, and other licensing news This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

This week's round-up of #pharmalicensingdeals features alliances involving #TenayaTherapeutics, #SinoBio, #Antengene, and #A2APharma.

pharmaphorum.com/news/alnylam...

Thiard News@F4F

@newsen.bsky.social

1 month ago

Antengene and UCB Forge Global Agreement for ATG-201 in Autoimmune Treatment Antengene partners with UCB to advance ATG-201, a bispecific T-cell engager antibody aimed at treating autoimmune diseases, marking a significant step in biopharmaceutical bonds.

Antengene and UCB Forge Global Agreement for ATG-201 in Autoimmune Treatment #None #UCB #Antengene #ATG-201

Thiard News@F4F

@newsen.bsky.social

1 month ago

Antengene Partners with UCB for Global License of ATG-201 T-Cell Engager Targeting Autoimmune Disorders Antengene and UCB have signed a global licensing agreement for ATG-201, a bispecific T-cell engager aimed at treating autoimmune diseases, showcasing innovative advancements in immunotherapy.

Antengene Partners with UCB for Global License of ATG-201 T-Cell Engager Targeting Autoimmune Disorders #Hong_Kong #UCB #Antengene #ATG-201

Thiard News@F4F

@newsen.bsky.social

1 month ago

XPOVIO® Gains Reimbursement Approval in South Korea for Multiple Myeloma Treatment Expansion Antengene Corporation's XPOVIO® has received approval for reimbursement in South Korea for multiple myeloma, benefiting more patients in the region.

XPOVIO® Gains Reimbursement Approval in South Korea for Multiple Myeloma Treatment Expansion #South_Korea #Seoul #XPOVIO #Multiple_Myeloma #Antengene

Thiard News@F4F

@newsen.bsky.social

1 month ago

Antengene and Junshi Biosciences Collaborate to Enhance Cancer Treatment Using ATG-037 and JS207 Antengene partners with Junshi Biosciences to investigate ATG-037 and JS207's combined potential in treating solid tumors, promising new therapies.

Antengene and Junshi Biosciences Collaborate to Enhance Cancer Treatment Using ATG-037 and JS207 #Cancer_Treatment #Antengene #Junshi_Biosciences

Thiard News@F4F

@newsen.bsky.social

2 months ago

Antengene Showcases Groundbreaking Advances at JPM Conference: What's Next for ADCs and TCEs? Antengene Corporation Limited presents significant clinical data and strategic directions for next-generation ADCs and TCEs at the JPM Healthcare Conference, highlighting their future potential.

Antengene Showcases Groundbreaking Advances at JPM Conference: What's Next for ADCs and TCEs? #USA #San_Francisco #Antengene #ADCs #TCEs

Thiard News@F4F

@newsen.bsky.social

3 months ago

Antengene Secures Approval for XPOVIO® to Treat DLBCL in Malaysia Antengene has achieved a significant milestone with the Malaysian approval of XPOVIO® for treating relapsed DLBCL, enhancing options for patients.

Antengene Secures Approval for XPOVIO® to Treat DLBCL in Malaysia #Malaysia #Kuala_Lumpur #DLBCL #Antengene #XPOVIO®

Thiard News@F4F

@newsen.bsky.social

4 months ago

Antengene's IND Approval in China for ATG-022 Clinical Study: A Step Forward in Cancer Treatment Antengene's ATG-022 receives IND approval in China for a pivotal clinical study. This innovative therapy aims to enhance treatment for specific cancers.

Antengene's IND Approval in China for ATG-022 Clinical Study: A Step Forward in Cancer Treatment #China #Shanghai #Antengene #KEYTRUDA #ATG-022

Thiard News@F4F

@newsen.bsky.social

4 months ago

Antengene's 2025 R&D Day Unveils Progress in Innovative Biotech Programs Antengene Corporation Limited presents significant advancements in clinical research during its 2025 R&D Day, focusing on innovative therapies for tumors and autoimmune diseases.

Antengene's 2025 R&D Day Unveils Progress in Innovative Biotech Programs #China #Shanghai #biotech #Clinical_Trials #Antengene

Thiard News@F4F

@newsen.bsky.social

5 months ago

Antengene Unveils Promising ATG-022 Clinical Data at ESMO 2025 with Broad Efficacy for CLDN18.2 Antengene Corporation Limited has shared its latest ATG-022 clinical trial findings at ESMO 2025, highlighting its efficacy and safety across varied CLDN18.2 expression levels.

Antengene Unveils Promising ATG-022 Clinical Data at ESMO 2025 with Broad Efficacy for CLDN18.2 #China #Shanghai #Antengene #ATG-022 #CLDN18.2

Thiard News@F4F

@newsen.bsky.social

5 months ago

Antengene Showcases Promising Efficacy of ATG-022 at ESMO 2025 for CLDN18.2 Expression Tumors Antengene Corporation Limited showcased ATG-022, an innovative cancer treatment, at ESMO 2025, showing efficacy in various expression levels with excellent safety.

Antengene Showcases Promising Efficacy of ATG-022 at ESMO 2025 for CLDN18.2 Expression Tumors #USA #Berlin #Antengene #ATG-022 #CLDN18.2

Thiard News@F4F

@newsen.bsky.social

6 months ago

Antengene Set to Showcase Innovative Preclinical Findings on ATG-201 at the Upcoming ACR 2025 Conference Antengene Corporation will unveil groundbreaking preclinical data on ATG-201 at ACR 2025, advancing treatment options for autoimmune diseases.

Antengene Set to Showcase Innovative Preclinical Findings on ATG-201 at the Upcoming ACR 2025 Conference #United_States #Chicago #Antengene #ATG-201 #CD19xCD3

Thiard News@F4F

@newsen.bsky.social

7 months ago

Antengene's 2025 Interim Results Showcase Promising Advances in Cancer Treatments and Innovative Technologies Antengene Corporation released its interim results for 2025, highlighting progress in clinical trials and new treatment strategies for cancer therapies.

Antengene's 2025 Interim Results Showcase Promising Advances in Cancer Treatments and Innovative Technologies #Shanghai #Antengene #ATG-022 #TCE_Platform

Thiard News@F4F

@newsen.bsky.social

7 months ago

Antengene's Recent Financial Results Showcase a Strong Clinical Pipeline and Innovative Therapeutic Advances Antengene Corporation Limited revealed its financial results for the first half of 2025, highlighting significant achievements in clinical programs and revenue growth.

Antengene's Recent Financial Results Showcase a Strong Clinical Pipeline and Innovative Therapeutic Advances #China #Shanghai #XPOVIO #Antengene #ATG-022

Thiard News@F4F

@newsen.bsky.social

7 months ago

Antengene's ATG-022 Receives Breakthrough Designation for Gastric Cancer Treatment Antengene Corporation’s ATG-022 has been awarded Breakthrough Therapy designation in China, paving the way for expedited development in gastric cancer treatment.

Antengene's ATG-022 Receives Breakthrough Designation for Gastric Cancer Treatment #China #Shanghai #gastric_cancer #Antengene #ATG-022

Thiard News@F4F

@newsen.bsky.social

7 months ago

Antengene's Breakthrough Therapy Designation for ATG-022 Marks a New Era in Gastric Cancer Treatment Antengene's ATG-022 has received Breakthrough Therapy designation for treating gastric and gastroesophageal junction cancers, offering new hope for patients.

Antengene's Breakthrough Therapy Designation for ATG-022 Marks a New Era in Gastric Cancer Treatment #China #Shanghai #Antengene #ATG-022 #Breakthrough_Therapy

Thiard News@F4F

@newsen.bsky.social

8 months ago

Antengene to Present Significant Findings on ATG-022 ADC at ESMO 2025 Antengene Corporation will showcase Phase I/II trial data of ATG-022, a Claudin 18.2 ADC, at ESMO 2025, highlighting its potential in treating gastric cancers.

Antengene to Present Significant Findings on ATG-022 ADC at ESMO 2025 #China #Shanghai #Antengene #ATG-022 #Claudin_18.2

Thiard News@F4F

@newsen.bsky.social

10 months ago

Antengene Unveils Promising Clinical Findings in CPI-Resistant Tumors at ASCO 2025 Event At ASCO 2025, Antengene showcased significant results from two studies on novel therapies targeting CPI-resistant solid tumors, underscoring their promising efficacy and safety.

Antengene Unveils Promising Clinical Findings in CPI-Resistant Tumors at ASCO 2025 Event #United_States #Chicago #Antengene #KEYTRUDA #ATG-037

Thiard News@F4F

@newsen.bsky.social

10 months ago

Antengene Collaborates with MSD to Explore Potent Cancer Treatment with ATG-022 and KEYTRUDA Antengene partners with MSD to assess the effectiveness of ATG-022 in conjunction with KEYTRUDA for advanced solid tumors, showcasing promising clinical data.

Antengene Collaborates with MSD to Explore Potent Cancer Treatment with ATG-022 and KEYTRUDA #China #Shanghai #Antengene #KEYTRUDA #ATG-022

Thiard News@F4F

@newsen.bsky.social

11 months ago

Antengene to Showcase Innovative Clinical Findings at ASCO 2025 Conference Antengene Corporation will present new clinical data for its small molecule inhibitors ATG-037 and ATG-008 at ASCO 2025, seeking advancements in cancer therapies.

Antengene to Showcase Innovative Clinical Findings at ASCO 2025 Conference #Antengene #ASCO_2025 #ATG-037

Thiard News@F4F

@newsen.bsky.social

1 year ago

Antengene Reports Remarkable Growth and Advancements in 2024 Financials and Clinical Trials Antengene Corporation Limited has shared impressive financial results for 2024, highlighting advancements in proprietary programs and multi-market expansion.

Antengene Reports Remarkable Growth and Advancements in 2024 Financials and Clinical Trials #China #Shanghai #XPOVIO #Clinical_Trials #Antengene

Thiard News@F4F

@newsen.bsky.social

1 year ago

Antengene's XPOVIO® Gains Approval in Indonesia, Strengthening APAC Expansion Antengene Corporation has achieved a significant milestone by receiving approval for XPOVIO® in Indonesia, expanding healthcare access in APAC.

Antengene's XPOVIO® Gains Approval in Indonesia, Strengthening APAC Expansion #XPOVIO #Antengene #Selinexor

Thiard News@F4F

@newsen.bsky.social

1 year ago

Antengene's XPOVIO® Gains Public Health Insurance Approval in Taiwan, Expanding Patient Access Antengene Corporation has announced that XPOVIO®, a treatment for relapsed/refractory multiple myeloma, is now covered by public health insurance in Taiwan, enhancing patient access.

Antengene's XPOVIO® Gains Public Health Insurance Approval in Taiwan, Expanding Patient Access #Taiwan #Taipei #XPOVIO #Multiple_Myeloma #Antengene

Thiard News@F4F

@newsen.bsky.social

1 year ago

Antengene Reports Promising Clinical Findings on Selinexor at ASH 2024 At ASH 2024, Antengene Corporation showcased key findings from two significant studies involving Selinexor, highlighting its potential in treating specific blood cancers.

Antengene Reports Promising Clinical Findings on Selinexor at ASH 2024 #China #Hong_Kong #Antengene #Selinexor #ASH2024